TAAR1 levels and sub-cellular distribution are cell line but not breast cancer subtype specific

[1]  G. Miller,et al.  Review and Meta-Analyses of TAAR1 Expression in the Immune System and Cancers , 2018, Front. Pharmacol..

[2]  M. Hoener,et al.  Trace Amines and Their Receptors , 2018, Pharmacological Reviews.

[3]  M. Shahid,et al.  Pharmacology of human trace amine‐associated receptors: Therapeutic opportunities and challenges☆ , 2017, Pharmacology & therapeutics.

[4]  N. Harbeck,et al.  Increased trace amine-associated receptor 1 (TAAR1) expression is associated with a positive survival rate in patients with breast cancer , 2017, Journal of Cancer Research and Clinical Oncology.

[5]  N. Harbeck,et al.  Breast cancer , 2017, The Lancet.

[6]  M. Disis,et al.  Clinical significance of tumor-infiltrating lymphocytes in breast cancer , 2016, Journal of Immunotherapy for Cancer.

[7]  H. Sørensen,et al.  Hypothyroidism and hyperthyroidism and breast cancer risk: a nationwide cohort study. , 2016, European journal of endocrinology.

[8]  M. Tschöp,et al.  Incretin-like effects of small molecule trace amine-associated receptor 1 agonists , 2015, Molecular metabolism.

[9]  G. Dernick,et al.  Trace amine-associated receptor 1 activation silences GSK3β signaling of TAAR1 and D2R heteromers , 2015, European Neuropsychopharmacology.

[10]  Frank Reimann,et al.  A Transcriptome-Led Exploration of Molecular Mechanisms Regulating Somatostatin-Producing D-Cells in the Gastric Epithelium , 2015, Endocrinology.

[11]  D. Grandy,et al.  Trace Amine-Associated Receptor 1 Localization at the Apical Plasma Membrane Domain of Fisher Rat Thyroid Epithelial Cells Is Confined to Cilia , 2015, European Thyroid Journal.

[12]  R. Gainetdinov,et al.  Postsynaptic D2 dopamine receptor supersensitivity in the striatum of mice lacking TAAR1 , 2015, Neuropharmacology.

[13]  A. Cimino-Mathews,et al.  Immune targeting in breast cancer. , 2015, Oncology.

[14]  M. Pornour,et al.  New perspective therapy of breast cancer based on selective dopamine receptor D2 agonist and antagonist effects on MCF-7 cell line. , 2015, Recent patents on anti-cancer drug discovery.

[15]  J. Xiang,et al.  HER2-directed therapy: current treatment options for HER2-positive breast cancer , 2015, Breast Cancer.

[16]  Raphael Gottardo,et al.  Orchestrating high-throughput genomic analysis with Bioconductor , 2015, Nature Methods.

[17]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[18]  A. Ghorpade,et al.  Methamphetamine and HIV-1-induced neurotoxicity: Role of trace amine associated receptor 1 cAMP signaling in astrocytes , 2014, Neuropharmacology.

[19]  Stephen R. Morairty,et al.  A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic- and antidepressant-like activity, improve cognition and control body weight , 2013, Molecular Psychiatry.

[20]  D. Krautwurst,et al.  Biogenic amines activate blood leukocytes via trace amine‐associated receptors TAAR1 and TAAR2 , 2013, Journal of leukocyte biology.

[21]  E. Vallender,et al.  Trace Amine Associated Receptor 1 Signaling in Activated Lymphocytes , 2012, Journal of Neuroimmune Pharmacology.

[22]  P. Erba,et al.  Distribution of exogenous [125I]-3-iodothyronamine in mouse in vivo: relationship with trace amine-associated receptors. , 2012, The Journal of endocrinology.

[23]  M. Millan,et al.  Evidence for functional trace amine associated receptor-1 in normal and malignant B cells. , 2012, Leukemia research.

[24]  Xi Chen,et al.  TNBCtype: A Subtyping Tool for Triple-Negative Breast Cancer , 2012, Cancer informatics.

[25]  T. Sotnikova,et al.  Functional Interaction between Trace Amine-Associated Receptor 1 and Dopamine D2 Receptor , 2011, Molecular Pharmacology.

[26]  X. Chen,et al.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. , 2011, The Journal of clinical investigation.

[27]  T. Sotnikova,et al.  TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity , 2011, Proceedings of the National Academy of Sciences.

[28]  Rafael A. Irizarry,et al.  A framework for oligonucleotide microarray preprocessing , 2010, Bioinform..

[29]  M. lenhard,et al.  Thyroid function in breast cancer patients. , 2010, Anticancer research.

[30]  Funda Meric-Bernstam,et al.  High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  M. Gassmann,et al.  The selective antagonist EPPTB reveals TAAR1-mediated regulatory mechanisms in dopaminergic neurons of the mesolimbic system , 2009, Proceedings of the National Academy of Sciences.

[32]  H. Iwaasa,et al.  Anatomical and histological profiling of orphan G-protein-coupled receptor expression in gastrointestinal tract of C57BL/6J mice , 2009, Cell and Tissue Research.

[33]  S. Coughlin,et al.  Anatomical Profiling of G Protein-Coupled Receptor Expression , 2008, Cell.

[34]  T. Sotnikova,et al.  Pharmacological Characterization of Membrane-Expressed Human Trace Amine-Associated Receptor 1 (TAAR1) by a Bioluminescence Resonance Energy Transfer cAMP Biosensor , 2008, Molecular Pharmacology.

[35]  Gianluca Bontempi,et al.  Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes , 2008, Clinical Cancer Research.

[36]  I. Drozdov,et al.  Luminal regulation of normal and neoplastic human EC cell serotonin release is mediated by bile salts, amines, tastants, and olfactants. , 2008, American journal of physiology. Gastrointestinal and liver physiology.

[37]  T. Hébert,et al.  G Protein-Coupled Receptors in and on the Cell Nucleus: A New Signaling Paradigm? , 2008, Journal of receptor and signal transduction research.

[38]  K. Bost,et al.  Expression of Neuronal Trace Amine-associated Receptor (Taar) mRNAs in Leukocytes , 2007, Journal of Neuroimmunology.

[39]  Ming Tan,et al.  Molecular mechanisms of erbB2-mediated breast cancer chemoresistance. , 2007, Advances in experimental medicine and biology.

[40]  D. Easton,et al.  Specific morphological features predictive for the basal phenotype in grade 3 invasive ductal carcinoma of breast , 2006, Histopathology.

[41]  J. Coebergh,et al.  Hypothyroidism might be related to breast cancer in post-menopausal women. , 2005, Thyroid : official journal of the American Thyroid Association.

[42]  C. Caldas,et al.  Molecular classification and molecular forecasting of breast cancer: ready for clinical application? , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  Jean YH Yang,et al.  Bioconductor: open software development for computational biology and bioinformatics , 2004, Genome Biology.

[44]  Sabina Frascarelli,et al.  3-Iodothyronamine is an endogenous and rapid-acting derivative of thyroid hormone , 2004, Nature Medicine.

[45]  Philip M. Long,et al.  Breast cancer classification and prognosis based on gene expression profiles from a population-based study , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[46]  A. Leon,et al.  HPLC electrochemical detection of trace amines in human plasma and platelets and expression of mRNA transcripts of trace amine receptors in circulating leukocytes , 2003, Neuroscience Letters.

[47]  R. Salgia,et al.  Recent advances in the molecular biology, diagnosis and novel therapies for various small blue cell tumors. , 2003, Anticancer research.

[48]  S. Demirbaş,et al.  Breast cancer in association with thyroid disorders , 2003, Breast Cancer Research.

[49]  D. Grandy,et al.  Amphetamine, 3,4-methylenedioxymethamphetamine, lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters are agonists of a rat trace amine receptor. , 2001, Molecular pharmacology.

[50]  R. Tibshirani,et al.  Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[51]  Beth Borowsky,et al.  Trace amines: Identification of a family of mammalian G protein-coupled receptors , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[52]  Y. Yarden,et al.  Untangling the ErbB signalling network , 2001, Nature Reviews Molecular Cell Biology.

[53]  E. Borrelli,et al.  Structure and function of dopamine receptors , 2000, Neuroscience & Biobehavioral Reviews.

[54]  Robert Clarke,et al.  Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines , 1992, Journal of cellular physiology.

[55]  L. Hegedüs,et al.  Thyroid function in patients with breast cancer. , 1987, European journal of cancer & clinical oncology.

[56]  D. Leo,et al.  Trace Amine-Associated Receptor 1 Modulation of Dopamine System , 2016 .

[57]  Baljit Singh,et al.  Breast cancer molecular subtypes: from TNBC to QNBC. , 2016, American journal of cancer research.

[58]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[59]  Guoying Liu,et al.  NetAffx: Affymetrix probesets and annotations , 2003, Nucleic Acids Res..

[60]  John Quackenbush,et al.  Genesis: cluster analysis of microarray data , 2002, Bioinform..

[61]  S. R. Nash,et al.  Dopamine receptors: from structure to function. , 1998, Physiological reviews.